Vico Therapeutics receives €11.5M in Series B funding to advance therapies for severe neurological conditions, building on a previous round of €54M earlier this year. Existing investors contributed to a total of €65.8M funding, aiming to make significant progress in treating these diseases.
The company's lead program, VO659, targets spinocerebellar ataxia types 3 and 1 and Huntington’s disease, currently lacking disease-modifying treatments. Vico Therapeutics uses precision chemistry in its VICOMER platform to design ASOs for RNA modulation with various approaches.
Seroba, a Dublin-based VC, supports Vico Therapeutics in advancing genetic medicines for severe neurological disorders. Seroba aims to drive value creation by investing in innovative biotech and medtech solutions that enhance patient care.
[
Collection
]
[
|
...
]